Vertex Pharmaceuticals (VRTX) stock rose 6.2% after Morgan Stanley upgraded its rating to &#34;Overweight&#34; with a new price target of $516, up from $438. This optimism is driven by the potential of Vertex's kidney drug pipeline, specifically Pove and Inaxaplin, ahead of their Phase 3 clinical trial data release in 2026. The stock's performance also reflects broader market sentiment, including hopes for interest rate cuts.

福泰制藥

<p>Vertex Pharmaceuticals (VRTX) 的股票上漲了 6.2%，因為摩根士丹利將其評級上調至 “增持”，並將目標價從 438 美元上調至 516 美元。這一樂觀情緒源於 Vertex 腎臟藥物管線的潛力，特別是 Pove 和 Inaxaplin，預計將在 2026 年發佈其三期臨牀試驗數據。該股票的表現也反映了更廣泛的市場情緒，包括對降息的期望</p>

為什麼福泰製藥 (VRTX) 的股票今天上漲